Copyright
©The Author(s) 2022.
World J Clin Oncol. Aug 24, 2022; 13(8): 712-724
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.712
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.712
Table 2 Details of cytochrome P450 2D6 genotyping for the 78 women classified into two phenotype groups: Intermediate metabolizers and extensive metabolizers/ultra metabolizers
Phenotype | CYP2D6 genotype | Number of women, n = 78 |
IM | *10/*10 | 25 |
*10/41 | 2 | |
*10/*4 | 2 | |
*10/*5 | 3 | |
*10/EM/UM | 20 | |
*5/EM/UM | 5 | |
EM/UM | EM/UM | 21 |
- Citation: Tan EY, Bharwani L, Chia YH, Soong RCT, Lee SSY, Chen JJC, Chan PMY. Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer. World J Clin Oncol 2022; 13(8): 712-724
- URL: https://www.wjgnet.com/2218-4333/full/v13/i8/712.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i8.712